Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark

The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, by the company was conducted in 150 patients, it added. Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy, Glenmark said.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news